Clinical Trial Update: The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effectiveness of adding alemtuzumab to CHOP and ESHAP regimens in newly diagnosed Peripheral T-cell lymphoma; the study has been com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CHOP regimen
• ESHAP regimen

Snippet

Sponsor: King Chulalongkorn Memorial Hospital | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED